Skip to main content
SpringerLink
Log in

Use of statins for secondary prevention

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

The causal role of hyperlipidemia in the pathogenesis of atherosclerosis is beyond dispute. The principal lipid abnormality responsible for coronary heart disease (CHD) is considered to be the elevation of the low-density lipoprotein cholesterol (LDL-C), although reduced levels of high-density lipoprotein cholesterol, and most recently elevated triglyceride levels, have also been associated with increased risk for CHD. The risk with these lipid abnormalities exists both in the asymptomatic population as well as in individuals with clinical evidence of atherosclerosis. Most patients with established CHD, and noncoronary atherosclerosis, will need drug therapy to achieve their National Cholesterol Education Program Adult Treatment Panel LDL-C goal of less than 100 mg/dL; the most efficacious, safe, and well-tolerated drugs for this purpose are the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins. The role of statins for secondary cardiovascular disease prevention has been well established in several large randomized clinical trials. New data now suggest that statins offer significant benefits to a broad range of patients at high global CHD risk, and should be regarded as an integral part of the management of acute coronary syndromes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2497.

  2. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000, 101:207–213.

    PubMed  CAS  Google Scholar 

  3. Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001, 35:1096–1107. A review of the literature covering reports of rhabdomyolysis with statin use.

    Article  PubMed  CAS  Google Scholar 

  4. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [no authors listed]. Lancet 1994, 344:1383–1389.

  5. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. New Engl J Med 1996, 335:1001–1009.

    Article  PubMed  CAS  Google Scholar 

  6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group [no authors listed]. New Engl J Med 1998, 339:1349–1357.

  7. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial, from the Heart Protection Collaborative Group [no authors listed]. Lancet 2002, 360:7–21. The largest and most recent randomized, placebo-controlled trial of statin use in high CHD risk individuals. Simvastatin use compared with placebo reduced CHD mortality, all vascular events, and all-cause mortality in these subjects, regardless of age, gender, or baseline LDL-C.

  8. Ballantyne CM, Olsson AG, Cook TJ, et al.: Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001, 104:3046–3051.

    PubMed  CAS  Google Scholar 

  9. Pedersen TR, Wilhelmsen L, Faergeman O, et al.: Followup study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 2000, 86:257–262.

    Article  PubMed  CAS  Google Scholar 

  10. Sacks FM, Tonkin AM, Shepherd J, et al.: Effects of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000, 102:1893–1900.

    PubMed  CAS  Google Scholar 

  11. Pitt B, Mancini JGB, Ellis SG, et al.: Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995, 26:1133–1139.

    Article  PubMed  CAS  Google Scholar 

  12. Jukerna JW, Bruschke AV, van Boven AJ, et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study. Circulation 1995, 91:2528–2540.

    Google Scholar 

  13. Blankenhorn DH, Azen SP, Kramsch DM, et al.: Coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993, 119:969–976.

    PubMed  CAS  Google Scholar 

  14. Waters D, Higginson L, Gladstone P, et al.: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994, 89:959–968.

    PubMed  CAS  Google Scholar 

  15. Herd JA, Ballantyne CM, Farmer JA, et al.: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevation (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997, 80:276–286.

    Article  Google Scholar 

  16. Effects of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) [no authors listed]. Lancet 1994,344:633–638.

  17. Jacobson TA: Clinical context: current concepts of coronary heart disease management. Am J Med 2001, 110:3S-11S.

    Article  PubMed  Google Scholar 

  18. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. Post Coronary Artery Bypass Graft Trial Investigators [no authors listed]. N Engl J Med 1997, 336:153–162.

  19. Furberg CD, Adams HP Jr, Applegate WB, et al.: Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994, 90:1679–1687.

    PubMed  CAS  Google Scholar 

  20. Stenestrand U, Wallentin L: Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001, 285:430–436.

    Article  PubMed  CAS  Google Scholar 

  21. Aronow HD, Topol EJ, Roe MT, et al.: Effect of lipid lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001, 357:1063–1068.

    Article  PubMed  CAS  Google Scholar 

  22. Newby LK, Kristinsson A, Bhapkar MV, et al.: Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002, 287:3087–3095.

    Article  PubMed  CAS  Google Scholar 

  23. Heeschen C, Hamm CW, Laufs U, et al.: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002, 105:1446–1452.

    Article  PubMed  CAS  Google Scholar 

  24. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711–1718. The first randomized trial of early statin initiation following unstable angina or non-Q-wave MI, with a 16-week evaluation of recurrent ischemic events.

    Article  PubMed  CAS  Google Scholar 

  25. Pitt B, Waters D, Brown WV, et al.: Aggressive lipidlowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999, 341:70–76.

    Article  PubMed  CAS  Google Scholar 

  26. Serruys PWJC, de Feyter P, Macaya C, et al.: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA 2002, 287:3215–3222.

    Article  PubMed  CAS  Google Scholar 

  27. American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.

    Google Scholar 

  28. Fonarow GC, French WJ, Parsons LS, et al.: Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001, 103:38–44.

    PubMed  CAS  Google Scholar 

  29. Pearson TA, Laurora I, Chu H, et al.: A multicenter survey to evaluate the percentage of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Int Med 2000, 160:459–467.

    Article  CAS  Google Scholar 

  30. Fonarow GC, Gawlinski A, Moughrabi S, et al.: Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001, 87:819–822. This in-hospital program, designed to improve the appropriate use of proven pharmacologic treatments that reduce CHD risk, has shown an increase in the discharge prescriptions for targeted drugs, increased post-hospital patient compliance to therapy, and improved outcomes.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, 6565 Fannin, M.S. A-601, 77030, Houston, TX, USA

    Antonios M. Xydakis MD & Peter H. Jones MD

Authors
  1. Antonios M. Xydakis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter H. Jones MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xydakis, A.M., Jones, P.H. Use of statins for secondary prevention. Curr Treat Options Cardio Med 5, 63–73 (2003). https://doi.org/10.1007/s11936-003-0015-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-003-0015-y

Keywords

Search

Navigation